Jun 19, 2020
FDA approves new Dupixent® (dupilumab) pre-filled pen designed to support more convenient self-administration
Jun 19, 2020
Dupixent® (dupilumab) Approved in China for Adults with Moderate-to-Severe Atopic Dermatitis
May 26, 2020
FDA Approves Dupixent® (dupilumab) as First Biologic Medicine for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
Apr 03, 2020
Dupixent® (dupilumab) Phase 3 Data at Revolutionizing Atopic Dermatitis Conference Show Significant Improvement in Severe Atopic Dermatitis for Children Aged 6 to 11 Years
Mar 24, 2020
Global Chronic Hand Eczema (CHE) Markets, Epidemiology, Drugs, Pipeline and Forecast to 2030
Feb 03, 2020
Atopic Dermatitis (AD) Industry Outlook to 2024 - Elaborate Pipelines of Pharmaceutical Companies Spurs Growth
Jan 31, 2020
GNO Snoring and Sinus Offers New Nasal Polyp Therapy
Jan 28, 2020
FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
Sep 20, 2019
CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis
Sep 06, 2019
Recent Studies Reveal Flare Rates Among Dupixent-Treated Patients with Moderate-to-Severe Atopic Dermatitis
Aug 06, 2019
Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis
Aug 06, 2019
Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Jun 28, 2019
CHMP Recommends Approval of Dupixent® (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents
Jun 26, 2019
FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis
Jun 21, 2019
Regeneron and Sanofi Announce Positive Topline Phase 2 Results for IL-33 Antibody in Asthma
May 07, 2019
Dupixent® (dupilumab) Approved for Severe Asthma by European Commission
Mar 11, 2019
FDA approves Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents
Mar 08, 2019
FDA to Undertake Priority Review of Dupixent® (dupilumab) for Adults with Inadequately Controlled Severe Chronic Rhinosinusitis with Nasal Polyps
Mar 01, 2019
CHMP Recommends Approval of Dupixent® (dupilumab) for Asthma Indication
Feb 27, 2019
Overall Use of Sanofi/Regeneron's Dupixent for the Treatment of Atopic Dermatitis in the EU5 Lags that of the US, Though Side Effects and Short-Term Use in Both Markets May be Cause for Concern